Table 4.

Summary of pharmacodynamic measures: CD19+ B cells (median and median percentage change from baseline).

	Ofatumumab
Measures	Placebo, n = 8	0.3 mg, n = 4	3 mg, n = 6	30 mg, n = 8	60 mg, n = 6	100 mg, n = 3
Mean baseline^a (GI/l)	0.201	0.178	0.172	0.213	0.341	0.234
Day 1 predose, n	8	4	6	7	5	2
Median day 1 predose (GI/l)	0.141	0.144	0.1545	0.202	0.315	0.182
Day 29, n	8	3	6	8	4	2
Median % change	3.206	−48.322	−73.147	−98.828	−99.024	−98.418
Minimum % change	−96.95	−63.31	−97.02	−99.27	−99.39	−98.99
Maximum % change	39.94	−29.57	−2.99	−82.96	−97.18	−97.84
Patients achieving target depletion
No. achieving target depletion (%)	1 (13)^b	0	1 (17)	7 (88)	6 (100)	3 (100)
No. achieving target depletion who started to replete (%)	1 (100)	0	1 (100)	4 (57)	6 (100)	3 (100)
Median time in days to start of repletion from target depletion (range)	43	0	43	72.5 (43–112)	99 (57–341)	85 (56–112)
Median time in days to repletion from target depletion (range)	43	0	337	590 (253–657)	266.5 (113–607)	280 (170–421)

↵^aBaseline is Day 1 predose value or the screening value if the Day 1 predose is missing.
↵^bPlacebo patient had unexplained target depletion at Day 29 and met repletion criterion at Day 43.